Demurtas_et_al_2020.docx (118.3 kB)
The efficacy and safety of influenza vaccination in older people: an umbrella review of evidence from meta-analyses of both observational and randomized controlled studies
journal contributionposted on 2023-08-30, 17:22 authored by Jacopo Demurtas, Stefano Celotto, Charlotte Beaudart, Dolores Sanchez-Rodriguez, Cafer Balci, Pinar Soysal, Marco Solmi, Daniele Celotto, Elena Righi, Lee Smith, Pierluigi Lopalco, Vania Noventa, Jean Michel, Gabriel Torbahn, Francesco Di Gennaro, Damiano Pizzol, Nicola Veronese, Stefania Maggi
Vaccination is the main public health intervention to prevent influenza. We aimed to evaluate the efficacy and safety of influenza vaccination including systematic reviews and meta-analyses of observational studies and randomized controlled trials (RCTs). Peer-reviewed systematic reviews with meta-analyses of prospective studies that investigated the association of influenza vaccination with any health-related outcome, as well as RCTs that investigated the efficacy and safety of influenza vaccination, were included. Among 1240 references, 6 meta-analyses were included. In cohort studies of community-dwelling older people influenza vaccination was associated with a lower risk of hospitalization for heart disease and for influenza/pneumonia (strength of evidence: convincing). Evidence in lowering the risk of mortality in community-dwelling older people, of all deaths/severe respiratory diseases in high risk community-dwelling older people and of hospitalization for influenza/pneumonia in case-control studies, was highly suggestive. In RCTs, influenza vaccination, compared to placebo/no intervention, was associated to higher risk of local tenderness/sore arm and to a reduced risk of influenza like-illness. Both these associations showed moderate evidence using the GRADE (Grading of Recommendations Assessment, Development and Evaluation). In conclusion, influenza vaccination in older people seems safe and effective. Further, the evidence on safety and efficacy of vaccines in this population might benefit by an extension of the follow-up period both in RCTs and in longitudinal studies, beyond the usual 6-month period, in order to be able to evaluate the impact of vaccination on long term outcomes.
Publication titleAgeing Research Reviews
- Accepted version